Marc Chadeau-Hyam

Marc Chadeau-Hyam

Auto-generated profile, based on publicly available information

Marc Chadeau-Hyam

School of Public Health, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in The Lancet
Verified
Journal Article
Open access
VRViviane Richard
Viviane Richard
CCCristian Carmeli
Cristian Carmeli
MJMarkus Jokela
Markus Jokela
PMPeter Muennig
Peter Muennig
FGFlorence Guida
Florence Guida
RTRosario Tumino
Rosario Tumino
In 2011, WHO member states signed up to the 25 × 25 initiative, a plan to cut mortality due to non-communicable diseases by 25% by 2025. However, socioeconomic factors influencing non-communicable diseases have not been included in the plan. In this study, we aimed to compare the contribution of socioeconomic status to mortality and years-of-life-lost with that of the 25 × 25 conventional risk factors. We did a multicohort study and meta-analysis with individual-level data from 48 independent prospective cohort studies with information about socioeconomic status, indexed by occupational position, 25 × 25 risk factors (high alcohol intake, physical inactivity, current smoking, hypertension, diabetes, and obesity), and mortality, for a total population of 1 751 479 (54% women) from seven high-income WHO member countries. We estimated the association of socioeconomic status and the 25 × 25 risk factors with all-cause mortality and cause-specific mortality by calculating minimally adjusted and mutually adjusted hazard ratios [HR] and 95% CIs. We also estimated the population attributable fraction and the years of life lost due to suboptimal risk factors. During 26·6 million person-years at risk (mean follow-up 13·3 years [SD 6·4 years]), 310 277 participants died. HR for the 25 × 25 risk factors and mortality varied between 1·04 (95% CI 0·98-1·11) for obesity in men and 2 ·17 (2·06-2·29) for current smoking in men. Participants with low socioeconomic status had greater mortality compared with those with high socioeconomic status (HR 1·42, 95% CI 1·38-1·45 for men; 1·34, 1·28-1·39 for women); this association remained significant in mutually adjusted models that included the 25 × 25 factors (HR 1·26, 1·21-1·32, men and women combined). The population attributable fraction was highest for smoking, followed by physical inactivity then socioeconomic status. Low socioeconomic status was associated with a 2·1-year reduction in life expectancy between ages 40 and 85 years, the corresponding years-of-life-lost were 0·5 years for high alcohol intake, 0·7 years for obesity, 3·9 years for diabetes, 1·6 years for hypertension, 2·4 years for physical inactivity, and 4·8 years for current smoking. Socioeconomic circumstances, in addition to the 25 × 25 factors, should be targeted by local and global health strategies and health risk surveillance to reduce mortality. European Commission, Swiss State Secretariat for Education, Swiss National Science Foundation, the Medical Research Council, NordForsk, Portuguese Foundation for Science and Technology.

1 July 2015 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
JCJohn C Chambers
John C Chambers
MLMarie Loh
Marie Loh
BLBenjamin Lehne
Benjamin Lehne
ADAlexander Drong
Alexander Drong
JKJennifer Kriebel
Jennifer Kriebel
JKJaspal S Kooner
Jaspal S Kooner

18 February 2020 in JAMA
Verified
Journal Article
Open access
PDF file
JEJoshua Elliott
Joshua Elliott
BBBarbara Bodinier
Barbara Bodinier
TBTom A. Bond
Tom A. Bond
MCMarc Chadeau-Hyam
Marc Chadeau-Hyam
EEEvangelos Evangelou
Evangelos Evangelou
ITIoanna Tzoulaki
Ioanna Tzoulaki
Cardiovascular disease (CVD) is the leading cause of death worldwide.1 Targeted CVD primary prevention strategies require timely identification of people at increased risk to focus effective lifestyle or pharmacological interventions. Risk prediction models have been developed to estimate the probability of developing cardiovascular outcomes in asymptomatic individuals.2 Currently, risk assessment guidelines from the American College of Cardiology and American Heart Association recommend lipid-lowering treatment for individuals with 10-year absolute risk of atherosclerotic CVD greater than 7.5% based on pooled cohort equations.3

12 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMatthew Whitaker
Matthew Whitaker
JEJoshua Elliott
Joshua Elliott
MCMarc Chadeau-Hyam
Marc Chadeau-Hyam
SRSteven Riley
Steven Riley
ADAra Darzi
Ara Darzi
PEPaul Elliott
Paul Elliott
Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study (n = 508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 (n = 97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services.

21 September 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BIBIOS-consortium
BIOS-consortium
NKNorihiro Kato
Norihiro Kato
CGCARDIo GRAMplusCD
CARDIo GRAMplusCD
LSLifeLines Cohort Study
LifeLines Cohort Study
TCThe InterAct Consortium
The InterAct Consortium
JCJohn C Chambers
John C Chambers

29 February 2024 in New England Journal of Medicine
Verified
Journal Article
Open access
AHAdam Hampshire
Adam Hampshire
AAAdriana Azor
Adriana Azor
CAChristina Atchison
Christina Atchison
WTWilliam Trender
William Trender
PHPeter J. Hellyer
Peter J. Hellyer
PEPaul Elliott
Paul Elliott
Cognitive symptoms after coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well-recognized. Whether objectively measurable cognitive deficits exist and how long they persist are unclear. We invited 800,000 adults in a study in England to complete an online assessment of cognitive function. We estimated a global cognitive score across eight tasks. We hypothesized that participants with persistent symptoms (lasting ≥12 weeks) after infection onset would have objectively measurable global cognitive deficits and that impairments in executive functioning and memory would be observed in such participants, especially in those who reported recent poor memory or difficulty thinking or concentrating ("brain fog"). Of the 141,583 participants who started the online cognitive assessment, 112,964 completed it. In a multiple regression analysis, participants who had recovered from Covid-19 in whom symptoms had resolved in less than 4 weeks or at least 12 weeks had similar small deficits in global cognition as compared with those in the no-Covid-19 group, who had not been infected with SARS-CoV-2 or had unconfirmed infection (-0.23 SD [95% confidence interval {CI}, -0.33 to -0.13] and -0.24 SD [95% CI, -0.36 to -0.12], respectively); larger deficits as compared with the no-Covid-19 group were seen in participants with unresolved persistent symptoms (-0.42 SD; 95% CI, -0.53 to -0.31). Larger deficits were seen in participants who had SARS-CoV-2 infection during periods in which the original virus or the B.1.1.7 variant was predominant than in those infected with later variants (e.g., -0.17 SD for the B.1.1.7 variant vs. the B.1.1.529 variant; 95% CI, -0.20 to -0.13) and in participants who had been hospitalized than in those who had not been hospitalized (e.g., intensive care unit admission, -0.35 SD; 95% CI, -0.49 to -0.20). Results of the analyses were similar to those of propensity-score-matching analyses. In a comparison of the group that had unresolved persistent symptoms with the no-Covid-19 group, memory, reasoning, and executive function tasks were associated with the largest deficits (-0.33 to -0.20 SD); these tasks correlated weakly with recent symptoms, including poor memory and brain fog. No adverse events were reported. Participants with resolved persistent symptoms after Covid-19 had objectively measured cognitive function similar to that in participants with shorter-duration symptoms, although short-duration Covid-19 was still associated with small cognitive deficits after recovery. Longer-term persistence of cognitive deficits and any clinical implications remain uncertain. (Funded by the National Institute for Health and Care Research and others.).